Subarachnoid hemorrhage
Drug research and approvals for subarachnoid hemorrhage: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 85 studies of subarachnoid hemorrhage are recruiting on ClinicalTrials.gov, Health Canada has authorized 7 drug trials for it since 2013, and FDA has 1 approved and 16 open orphan designations naming it.
- Recruiting worldwide: 85
- Trials authorized in Canada: 7
- FDA orphan approvals: 1
- EU medicines: 0
- Follow-up of Unruptured Intracranial Aneurysms With Ultra-High Field 7 Tesla MRINCT07949903 · Not applicable · Insel Gruppe AG, University Hospital Bern · starts Dec 18, 2024
- Swiss Pilot Screening Study for Unruptured Intracranial Aneurysms to Prevent Subarachnoid Hemorrhage in SmokersNCT07938775 · Not applicable · Insel Gruppe AG, University Hospital Bern · starts Jul 28, 2023
- Determining the Clinical Impact and Prevalence of Hemorrhagic Subtypes in Perimesencephalic Subarachnoid HemorrhageNCT07923084 · Not reported · Insel Gruppe AG, University Hospital Bern · starts Jan 1, 2026
- Smartphone Enabled Detection of Cognitive Motor Dissociation in the ICUNCT07917728 · Not reported · Columbia University · starts Oct 27, 2026
- French Validation of the SAHOT Outcome Scale After Subarachnoid HaemorrhageNCT07894666 · Not reported · Fondation Ophtalmologique Adolphe de Rothschild · starts Sep 28, 2026
- AI-based Algorithm Development for Improved Diagnostics in the Intensive Care and Acute Stroke Setting Using…NCT07886957 · Not reported · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · starts Mar 26, 2026
- Metabolomics in Subarachnoid HemorrhageNCT07865182 · Not reported · Unidade Local de Saude Sao Jose · starts May 1, 2025
- Multimodal Assessment and Prognosis in Disorders of Consciousness After Severe Brain Injury (CyDoC-MAP)NCT07736820 · Not reported · Nicosia General Hospital · starts Oct 1, 2026
- Diagnosis and Treatment of Late Neurological Ischemic Deficit in Patients Suffering From Subarachnoid Hemorrhage.NCT07634172 · Not reported · Société Française d'Anesthésie et de Réanimation · starts Aug 28, 2026
Phase 3 11
- ClazosentanEndothelin receptor ET-A antagonist
- NimodipineMineralocorticoid receptor antagonist
- SimvastatinHMG-CoA reductase inhibitor
- PropofolGABA-A receptor; anion channel positive allosteric modulator
- Fospropofol
- BivalirudinThrombin inhibitor
- AlteplaseTissue-type plasminogen activator exogenous protein
- HeparinAntithrombin-III activator
- LevetiracetamSynaptic vesicle glycoprotein 2A modulator
- DexamethasoneGlucocorticoid receptor agonist
- DexmedetomidineAdrenergic receptor alpha-2 agonist
Phase 2 12 of 17
- Nitrous acid
- DeferoxamineIron chelating agent
- BaricitinibTyrosine-protein kinase JAK1 inhibitor
- FentanylMu opioid receptor agonist
- MidazolamGABA-A receptor; anion channel positive allosteric modulator
- Tranexamic acidPlasminogen inhibitor
- Fludrocortisone acetateMineralocorticoid receptor agonist
- EpoprostenolProstanoid IP receptor agonist
- KetamineGlutamate [NMDA] receptor negative allosteric modulator
- NicardipineVoltage-gated L-type calcium channel blocker
- MilrinonePhosphodiesterase 3A inhibitor
- SevofluraneGlycine receptor (alpha-1/beta) positive modulator
Phase 1 or earlier 5
- EtanerceptTNF-alpha inhibitor
- GalantamineAcetylcholinesterase inhibitor
- Albumin humanBilirubin sequestering agent
- Mannitol
- BupivacaineSodium channel protein type IV alpha subunit blocker
How its trials ended
466 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 89 whose ending is known, 22% met their primary endpoint, 13% missed it and 64% stopped early.
- Completed, result not reported16235%
- Ongoing12126%
- Status unknown9420%
- Stopped: other or unclear296%
- Met its primary endpoint204%
- Stopped: enrollment or feasibility194%
- Missed its primary endpoint123%
- Stopped: lack of efficacy72%
- Stopped: sponsor or business decision1<1%
- Stopped: funding1<1%
| Jun 25, 2024 | Safety and tolerability of GTX-104 (nimodipine injection for iv infusion) compared with oral nimodipine in patients hospitalized for aneurysmal subarachnoid…Nimodipine (GTX-104) | Grace Therapeutics | Pending |
| Aug 21, 2018 | A prospective, multi-center, double-blind, randomized, placebo-controlled, parallel-group, phase 3 study to assess the efficacy and safety of clazosentan in…Clazosentan | Idorsia Pharmaceuticals Ltd | Ongoing |
| Aug 8, 2016 | Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study comparing EG-1962 to standard of care oral…Nimovent (EG-1962) | Edge Therapeutics Inc | Ongoing |
| May 1, 2015 | A pilot study of sub-anesthetic ketamine infusion for neuroprotection after aneurysmal subarachnoid hemorrhage: effects on white matter integrity, inflammatory…Ketamine | Dr Andrew Baker | Closed |
| Apr 16, 2014 | A phase 2, multicenter randomized, double-blind, placebo-controlled, safety and efficacy study evaluating a single dose of intravenous na 1 in patients with…NA-1 | Nono Inc | Pending |
| Oct 9, 2013 | Ultra-early tranexamic acid after subarachnoid hemorrhageTranexamic acid | St Michaels Hospital | Pending |
| Jul 26, 2013 | Phase 1/2a multicenter, controlled, randomized, open-label, dose escalation, safety, tolerability, and pharmacokinetic study comparing EG-1962 and nimodipine…Nimovent (EG-1962) | Edge Therapeutics Inc | Closed |
| May 10, 2013 | NymalizeImprovement of neurological outcome by reducing the incidence and severity of ischemic deficits in adult patients with subarachnoid… | Arbor Pharmaceuticals, Inc. | Approved |
| Dec 26, 2024 | CeriopolymexTreatment of subarachnoid hemorrhage | Cenyx Biotech Inc. | Designated |
| Aug 1, 2023 | Nimodipine intravenousTreatment of subarachnoid hemorrhage | Cipla Ltd. | Designated |
| Oct 12, 2021 | Haptoglobin (Hp1-1), (Human)Treatment of subarachnoid hemorrhage | CSL Behring | Designated |
| Nov 17, 2020 | (R)-6-(2-hydroxy-3-(4-(4-(trifluoromethyl)phenyl)piperazin-…Treatment of subarachnoid hemorrhage | NeurOp Inc. | Designated |
| Sep 9, 2020 | LumacaftorTreatment of subarachnoid hemorrhage | Qanatpharma AG | Designated |
| Sep 5, 2019 | FasudilTreatment of subarachnoid hemorrhage | Aneuryst, Inc. | Designated |
| Mar 28, 2018 | MelatoninTreatment of subarachnoid hemorrhage | WORPHMED Srl | Designated |
| Aug 10, 2017 | Nimodipine intravenousTreatment of subarachnoid hemorrhage | Grace Therapeutics U.S., Inc. | Designated |
| Aug 3, 2017 | 1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio] butadieneTreatment of subarachnoid hemorrhage (SAH) | Edvince AB | Designated |
| Aug 22, 2016 | Stabilized sulforaphaneTreatment of subarachnoid hemorrhage | Evgen Pharma PLC | Designated |
| Feb 8, 2016 | GlyburideTreatment of acute subarachnoid hemorrhage | Remedy Pharmaceuticals, Inc. | Designated |
| May 28, 2015 | Intraventricular nimodipineTreatment of subarachnoid hemorrhage | Edge Therapeutics, Inc. | Designated |
| May 14, 2013 | H-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-alys-aleu-Ser-…Treatment of subarachnoid hemorrhage | NoNO, Inc. | Designated |
| Jan 17, 2007 | Sodium nitritePrevention of vasospasm associated with subarachnoid hemorrhage | Hope Pharmaceuticals | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA